Dr. Rosenberg on Non-Metastatic Muscle Invasive Bladder Cancer Guidelines
Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.
Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center and BCAN Scientific Advisor, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.
Traditionally, the only treatment for muscle invasive bladder cancer was radical cystectomy, explains Rosenberg. Following several large randomized trials, there has been a shown benefit to cisplatin-based neoadjuvant chemotherapy prior to cystectomy.
The new guidelines establish cisplatin-based neoadjuvant chemotherapy as a standard of care for these patients, states Rosenberg.
